VSTM
Verastem, Inc.
Biotechnology · Healthcare · United States
9.75
close · 2026-10-30
value
28
cheaper than peers28
quality
33
stronger fundamentals33
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, 3 years ago | -5.4% | 56 |
| cash flow yield, 1 year ago | -8.8% | 53 |
| cash flow yield, 2 years ago | -7.3% | 52 |
| cash flow yield, latest year | -12.4% | 46 |
| price to sales | 13.53× | 45 |
| earnings yield, 2 years ago | -40.6% | 34 |
| earnings yield, latest year | -31.0% | 33 |
| earnings yield, 1 year ago | -37.5% | 32 |
| earnings yield, 3 years ago | -46.9% | 31 |
| price to book | 17.66× | 11 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 1775.4% | 95 |
| operating margin | -81.6% | 57 |
| debt to equity | 168.7% | 14 |
| return on equity | -471.2% | 3 |
4 of 4 measures available
Facts
| market cap | $1B |
| free cash flow | -$103.4M |
| employees | 102 |
| first trade | 2012-01-27 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.02 | -3.66 | -3.96 | -4.57 |
| free cash flow | -$147.1M | -$104.8M | -$86.5M | -$63.7M |
| net income | -$209.5M | -$130.6M | -$87.4M | -$73.8M |
| revenue | $30.9M | $10.0M | $0 | $2.6M |
| unusual items | -$29.3M | -$19.1M | $0 | $0 |